Asia Pacific Antibody Drug Conjugates Market Size, Share, and COVID-19 Impact Analysis, By Product (Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy, and Others), By Application (Blood Cancer, Breast Cancer, Urothelial Cancer & Bladder Cancer, and Others), and Asia Pacific Antibody Drug Conjugates Market Insights, Industry Trend, Forecasts to 2035.

Asia Pacific Antibody Drug Conjugates Market Insights Forecasts To 2035

• The Asia Pacific Antibody Drug Conjugates Market Size was Estimated at USD 2.01 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 16.61% from 2025 to 2035
• The Asia Pacific Antibody Drug Conjugates Market Size is Expected to Reach USD 10.90 Billion by 2035

According to a research report published by Spherical Insights & Consulting, The Asia Pacific Antibody Drug Conjugates Market Size is Anticipated To Reach USD 10.90 Billion by 2035, Growing at a CAGR of 16.61% from 2025 to 2035. The increasing availability of targeted therapeutics, along with the growing prevalence of cancer and focus on oncology research, is driving the antibody drug conjugates market in the Asia Pacific region.

Market Overview

The Asia Pacific antibody drug conjugates market refers to the industry of engineered cancer therapies where a potent, cell-killing drug (payload) is attached to a monoclonal antibody via a linker. Antibody drug conjugates refer to cancer treatment in which targeted therapy and chemotherapy are combined. They deliver chemotherapy drugs to specific cancerous cells, damaging or destroying cancerous cells without harming nearby healthy cells. The growing cancer prevalence, along with the upsurging need for effective, low-toxic drugs, is propelling the market for antibody drug conjugates. Technological advancements, including antibody discovery/engineering, are paving the way for ADCs as potent therapies targeting solid tumors and hematological malignancies. Adoption of combination therapies using antibody-drug conjugates, which is an appealing strategy for pharmaceutical and biotechnology businesses, provides a significant market growth opportunity for antibody drug conjugates.

Report Coverage

This research report categorizes the market for the Asia Pacific antibody drug conjugates market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Asia Pacific antibody drug conjugates market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Asia Pacific antibody drug conjugates market.

Driving Factors

The market for Asia Pacific antibody drug conjugates is primarily driven by antibody drug conjugates as targeted therapeutics in the treatment of hematologic and solid malignancies. The investment and collaborations for driving the development and manufacturing capabilities of ADCs contribute to drive the market growth. Additionally, the growing prevalence of cancer, along with the increasing advancement in ADC technology, is responsible for significantly driving the antibody drug conjugates market.

Restraining Factors

The technical complexities and side effects associated with ADCs are responsible for restraining the market growth. Further, the lack of reimbursement scenarios, especially in developing economies, poses a challenge in the antibody drug conjugates market.

Market Segmentation

The Asia Pacific Antibody Drug Conjugates market share is classified into product and application.

• The kadcyla segment held the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Asia Pacific antibody drug conjugates market is segmented by product into kadcyla, enhertu, adcetris, padcev, trodelvy, polivy, and others. Among these, the kadcyla segment held the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period. Kadcyla is a HER2-targeted antibody drug conjugate, which is approved for late-stage breast cancer. An increasing number of ADCs in clinical trials, along with an increasing cancer prevalence, is driving the market.  

• The breast cancer segment held a dominant revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Asia Pacific antibody drug conjugates market is segmented by application into blood cancer, breast cancer, urothelial cancer & bladder cancer, and others. Among these, the breast cancer segment held a dominant revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period. ADCs aid in selectively delivering cytotoxic drugs into the cancer cells, without causing damage to healthy tissues. The growing prevalence of breast cancer, along with the surging demand for targeted therapies, is contributing to promoting market demand.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Asia Pacific antibody drug conjugates market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Daiichi Sankyo Co., Ltd.
• RemeGen Co., Ltd.
• Mycenax Biotech Inc.
• Mabwell (Shanghai) Bioscience Co., Ltd.
• Biocon Biologics Ltd.
• WuXi Biologics (Cayman) Inc.
• Samsung Biologics Co., Ltd.
• Bio-Thera Solutions, Ltd.
• Prestige Biopharma Ltd.
• Kyowa Kirin Co., Ltd.
• Innovent Biologics, Inc.
• Nanjing Leads Biolabs Co., Ltd.
• Tot Biopharm Co., Ltd.
• Others

Recent Developments:

• In May 2025, RemeGen’s Disitamab Vedotin gained approval in China for its Third indication making it the first ADC approved for HER2-positive advanced breast cancer with liver metastasis.
• In December 2024, Porton Pharma Solutions and Dragon Sail Pharmaceutical (Shanghai) signed a strategic cooperation agreement in Guilin, southern China. The collaboration aims to carry out in-depth cooperation in the research, development, production, and supply chain integration of antibody-drug conjugates (ADC).
• In November 2024, AstraZeneca breaks ground on a new Antibody Drug conjugate (ADC) manufacturing facility in Singapore. AstraZeneca has committed $1.5 billion, its largest first-stage investment to date, to establish the facility spanning 58 acres (more than 2.5 million square feet).

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Asia Pacific, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Asia Pacific Antibody Drug Conjugates Market based on the below-mentioned segments:

Asia Pacific Antibody Drug Conjugates Market, By Product

• Kadcyla
• Enhertu
• Adcetris
• Padcev
• Trodelvy
• Polivy
• Others

Asia Pacific Antibody Drug Conjugates Market, By Application

• Blood Cancer
• Breast Cancer
• Urothelial Cancer & Bladder Cancer
• Others